In contrast, outcome in MLL-rearranged infant ALL has stagnated over the last decades and novel treatment rationales are urgently required; the results from the present study, particularly in the context of the clinical data on irinotecan treatment in literature, suggest that TOP1 inhibitors may indeed be a valuable addition to infant ALL treatment protocols. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.